donepezil + rivastigmine

Donepezil + rivastigmine is a combination of two cholinesterase inhibitors, both approved for the symptomatic treatment of mild to moderate dementia in Alzheimer's disease. Both drugs work by inhibiting acetylcholinesterase, thereby increasing acetylcholine concentrations at synapses in the brain and enhancing cholinergic neurotransmission. Rivastigmine also inhibits butyrylcholinesterase, providing a broader spectrum of cholinesterase inhibition compared to donepezil. These agents do not alter the underlying progression of Alzheimer's disease but may temporarily alleviate or stabilize cognitive symptoms such as memory loss and confusion[1][6][8]. The combination is not an established or marketed fixed-dose product; rather, these medications are sometimes co-prescribed off-label under special circumstances due to overlapping mechanisms and increased risk for adverse effects[2].